Genomic Service List

Size: px
Start display at page:

Download "Genomic Service List"

Transcription

1 Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: 1 of 5 WHOLE GENOME SEQUENCING Human Whole Genome Sequencing 1 HGG-15 Human Whole Genome Sequencing HGG-157 (FASTQ data only) WHOLE EXOME SEQUENCING Human Whole Exome Sequencing 1 HGE-16 Human Whole Exome Sequencing HGE-17 (FASTQ data only) INHERITED DISORDERS TARGETED PANELS HGT-18 HGT-19 HGT-130 HGT-131 HGT-133 Comprehensive Autism Panel Comprehensive Cardio-vascular Panel Comprehensive Cardio-myopathy Panel (incl. full bioinformatics analysis & report) Sudden Cardiac Arrest Panel Diabetes MODY Panel WGS (30x) WGS (30x) WES (<30X) WES 61 genes 9 genes 67 genes 613 genes 1 genes Whole Genome 1 EDTA Blood 30,000 Whole Genome 1 EDTA Blood 0,000 Whole exome of 5,000 genes 3 Whole exome of 5,000 genes 3 ADSL, AFF, ALDH5A1, AP1S, ARX, ATRX, BRAF, CACNA1C, CASK, CDKL5, CHD7, CHD8, CNTNAP, CREBBP, CYP7A1, DHCR7, DMD, EHMT1, FGD1, FMR1, FOLR1, FOXG1, FOXP1, FOXP, HPRT1, KDM5C, L1CAM, MAGEL, MBD5, MECP, MED1, MEFC, MID1, NHS, NIPBL, NLGN3, NLGN4X, NR1I3, NRXN1, NSD1, OPHN1, PAFAH1B1, PCDH19, PHF6, PNKP, PQBP1, PTCHD1, PTEN, PTPN11, RAB39B, RAI1, RELN, SCN1A, SLCA1, SLC9A6, SMARCB1, SMC1A, TCF4, UBEA, UBE3A, VPS13B ABCC9, ACTN, ANK, ANKRD1, BAG3, CACNA1C, DMD, DSG, DSP, KCNE, KCNH, LDB3, MYBPC3, MYH6, MYL3, MYPN, PKP, RYR, SCN5A, SOS1, TTN, TTR, VCL, FBN1, CHD7, NOTCH1, COL4A3, EHMT1, SMAD4 ABCC9, ACTC1, ACTN, ANKRD1, BAG3, BRAF, CALR3, CASQ, CAV3, CRYAB, CSRP3, CTNNA3, DES, DMD, DSC, DSG, DSP, DTNA, EMD, FHL1, FKTN, GAA, GATAD1, GLA, HRAS, JPH, JUP, KRAS, LAMA4, LAMP, LDB3, LMNA, MAPK1, MAPK, MYBPC3, MYH6, MYH7, MYL, MYL3, MYOZ, MYPN, NEBL, NEXN, NRAS, PDLIM3, PKP, PLN, PRKAG, PTPN11, RAF1, RBM0, RYR, SCN5A, SGCD, SLCA5, SOS1, TAZ, TCAP, TGFB3, TMEM43, TNNC1, TNNI3, TNNT, TPM1, TTN, TTR, VCL ANK, CASQ, CAV3, KCNE1, KCNE, KCNH, KCNJ, KCNQ1, RYR, SCN5A, CALM1, CALM3, KCND3 ABCC8, BLK, GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11, KLF11, NEUROD1, PAX4, PDX1 8,000 6,600 5, MBG Lab recommends analysing relatives (proband plus parents; or siblings) to provide the most accurate interpretation of these s. MBG Lab P.O. Box 597, Dubai, UAE T: F: E: info@mbg.ae Web: :36PM

2 Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: of 5 HGT-134 HGT-135 HGT-136 HGT-137 HGT-138 HGT-139 HGT-140 HGT-141 HGT-143 Comprehensive Epilepsy Panel Gastro-Intestinal Panel Mitochondrial Disorder Panel (Nuclear genes only) Mitochondrial Whole Genome Analysis (incl. full bioinformatics analysis & report) Congenital Muscular Dystrophy Panel LGMD Muscular Dystrophy Panel Neuro-Muscular Panel Cystic Fibrosis &Pulmonary Disease Panel Deafness Panel 64 genes 1 genes 35 genes 14 genes 30 genes 34 genes 54 genes 51 genes 3 genes ADSL, ALDH7A1, ARHGEF9, ARX, ATP1A, ATP6AP, CACNA1A, CASK, CDKL5, CHRNA, CHRNA4, CHRNB, CLN3, CLN5, CLN6, CLN8, CNTNAP, CSTB, CTSD, DNAJC5, EPMA, FOLR1, GABRA1, GABRG, GAMT, GOSR, GRINA, KCNJ10, KCNQ, KCNQ3, KCTD7, LGI1, MBD5, MECP, MEFC, MFSD8, NHLRC1, NRXN1, OPHN1, PCDH19, PHF6, PLCB1, PNKP, PNPO, POLG, PPT1, PRICKLE1, PRRT, SCARB, SCN1A, SCN1B, SCNA, SCN8A, SLC5A, SLCA1, SLC9A6, SPTAN1, STXBP1, TBC1D4, TCF4, TPP1, TSC1, UBE3A, ZEB ABCB11, ABCB4, ABCC, ATP7B, BAAT, EPCAM, FAH, G6PC, JAG1, SLC10A, TJP, UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, VIPAS39 ATPAF, BCS1L, COX10, COX15, COX4I, COX6B1, FASTKD, FOXRED1, LRPPRC, NDUFA1, NDUFA10, NDUFA11, NDUFA, NDUFAF1, NDUFAF3, NDUFAF4, NDUFAF5, NDUFS1, NDUFS, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NUBPL, SCO1, SCO, SDHAF1, SURF1, TACO1, TMEM70, TTC19, UQCRB, UQCRQ MT-ATP6, MT-ATP8, MT-CO1, MT-CO, MT-CO3, MT-CYB, MT-ND1, MT-ND, MT- ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-RNR CHKB, COL6A1, COL6A, COL6A3, FKRP, FKTN, ITGA7, LAMA, LMNA, RYR1, SEPN1, ACTA1, CFL, DAG1, DPM1, DPM3, ISPD, KBTBD13, LARGE, MEGF10, MTM1, NEB, POMGNT1, POMT1, POMT, SYNE1, TCAP, TNNT1, TPM, TPM3 ANO5, CAPN3, CAV3, DES, DMD, DYSF, FKRP, FKTN, GAA, LMNA, MYOT, POMGNT1, POMT1, POMT, SGCA, SGCB, SGCD, SGCG, TCAP, TRIM3, TTN, COL6A1, COL6A, COL6A3, DAG1, DNAJB6, EMD, FHL1, FLNC, GNE, ISPD, PLEC, SYNE1, VCP ACTA1, ANO5, BAG3, BIN1, CAPN3, CAV3, CFL, COL6A1, COL6A, COL6A3, CRYAB, DAG1, DES, DMD, DNM, DYSF, EMD, FHL1, FKRP, FKTN, FLNC, GAA, GNE, IGHMBP, ISPD, ITGA7, LAMA, LARGE, LDB3, LMNA, MTM1, MYH7, MYOT, NEB, PLEC, POMGNT1, POMT1, POMT, PYGM, RYR1, SCN4A, SEPN1, SGCA, SGCB, SGCD, SGCG, TCAP, TNNI, TNNT1, TPM, TPM3, TRIM3, TTN, VRK1 CFTR, SFTPB, ABCA3, ACVRL1, AP3B1, ASCL1, BDNF, BLOC1S3, BLOC1S6, BMPR, CCDC39, CCDC40, CSFRA, DNAAF1, DNAAF, DNAH11, DNAH5, DNAI1, DNAI, DNAL1, DOCK8, DTNBP1, EDN3, EFEMP, ELN, ENG, FBLN5, FLCN, GDNF, HPS1, HPS3, HPS4, HPS5, HPS6, LTBP4, NME8, PHOXB, RET, RSPH4A, RSPH9, SCNN1A, SCNN1B, SCNN1G, SERPINA1, SFTPC, SFTPD, SMAD9, S3, TERT, TSC1, TSC CDH3, CLDN14, COL4A4, EDN3, GJB, HGF, LARS, LOXHD1, LRTOMT, MARVELD, MYO15A, MYO6, MYO7A, OTOF, PCDH15, POU4F3, PTPRQ, SCARF, SLC6A4, TMC1, UBIAD1, USHA, WFS1 0,600 MBG Lab P.O. Box 597, Dubai, UAE T: F: E: info@mbg.ae Web: :36PM

3 Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: 3 of 5 HGT-144 HGT-145 HGT-146 HGT-147 HGT-148 HGT-149 HGT-151 HGT-150 Dysmorphic - Dysplasia Panel Endocrine Disorder Panel Metabolic Disorder Panel Neurological Disorder Panel Pelvic Inflammatory Disease Panel Renal Disease Panel Warfarin sensitivity Panel Visual Disorder Panel 6 genes 5 genes 40 genes 110 genes 9 genes 1 genes genes 80 genes EVC, EXT1, EZH, FBN1, FGFR, FGFR3, FKBP10, FREM1, GALNS, GNPAT, HGSNAT, HRAS, HSPG, IFT1, IRF6, KMTD, LEPRE1, LIFR, LMNA, MASP1, MGAT, MMP, NEK1, NF1, NFIX, NIPBL, NSD1, OBSL1, PCNT, PEX13, PYCR1, RIPK4, ROR, SERPINF1, SGSH, TCOF1, TMEM67, TNFRSF11B, UBR1, WISP3 BBS5, GHR, GHRHR, SHOX, TBCE ACADM, AMT, ARG1, ARSB, ASAH1, ASL, ASS1, BCKDHA, BCKDHB, BTD, CBS, CLN8, CPS1, DBT, DPAGT1, FAH, G6PC, GAA, GBA, GCDH, GLB1, GNS, H6PD, HSD3B7, IVD, LHGDH, MCCC, MMACHC, MMADHC, MUT, OXCT1, PAH, PEX1, PGM1, PHKG, PTS, PYGL, SLCA5, SLC37A4, SLC3A1 ABAT, ABCD1, ABHD1, ADCK3, ADK, ADRAB, AGRN, AHI1, ALS, ARFGEF, ARHGEF6, ARID1B, ARL13B, ARL14EP, ASPM, ATL1, ATN1, ATRX, C1orf57, C5orf4, CACNA1G, CAPN3, CASC5, CCDC88C, CDK5RAP, CDKL5, CENPJ, CEP57, CLN6, COG6, COL6A1, COL6A, COL6A3, CPA6, CYP7A1, DPYD, DYSF, ERLIN, FKRP, FKTN, FLVCR, FOXG1, GDAP1, GNE, HEPACAM, HEXA, HSD17B4, HUWE1, ISPD, KIAA0196, KIF1A, KIF7, L1CAM, LAMA, LARGE, LRPPRC, MCPH1, MECP, MED3, MFSD8, MPDZ, NDE1, NPC, NTRK1, OCLN, OPTN, PANK, PEX1, PEX1, PEX16, PEX6, PEX5, PEX6, PHGDH, PLAG6, PLP1, PNPO, POMT1, POMT, PSAP, RELN, RNASEHB, RNASEHC, RYR1, SCNA, SEPN1, SGCA, SGCB, SLC5A19, SOD1, SPG11, SPG0, SPTBN, STXBP1, SYNE, SYNGAP1, TCTN1, TMEM37, TMEM67, TRAPPC9, TRMT1, TUBA1A, TYMP, VAPB, WDR45B, WDR6, WDR81, WNK1, YARS, ZNF56 ADA, AICDA, AIRE, AK, ATM, BTK, CD47, CD40, CD40LG, COLEC11, CYBB, DCLRE1C, DNMT3B, DOCK8, FLG, IL7R, JAK3, LYST, MLPH, NCF, NHEJ1, PTPRC, RAB7A, RAG1, RAG, RFXANK, SLC17A5, S3, WAS C5orf4, CCDA, CEP90, COL4A4, COL4A6, FRAS1, IQCB1, LAMB, MKS1, NEK8, NPHP3, NPHP4, NPHS1, PKHD1, SLC4A4, SMARCAL1, TCTN, TMEM37, TMEM67, UPK3A, XDH CYPC9, VKORC1 ABCA4, ADAM9, AIPL1, ALMS1, ARL6, BBS1, BBS10, BBS, BBS4, BBS5, BBS7, BBS9, BEST1, C8orf37, CACNA1F, CDHR1, CEP90, CERKL, CHD7, CHM, CHST6, CNGA3, CNGB1, CNNM4, CRB1, CRX, CRYAA, CRYBA1, CRYGC, CRYGD, CYP1B1, EFEMP1, EPHA, EYS, FAM161A, FZD4, GALT, GCNT, GDF3, GPR179, GUCYD, IGFBP7, IMPG, KCNJ13, KCNV, LCA5, LRAT, LRP5, LTBP, MERTK, MFRP, MIP, MYO7A, NHS, NMNAT1, NPHP4, NRE3, PAX6, PDE6C, PROM1, PRPH, PRSS56, RAB3GAP1, RAB3GAP, RDH1, RGS9, RLBP1, RP1, RP1L1, RP, RPE65, RPGRIP1, SLC16A1, SLC4A11, SNRNP00, SPATA7, TRPM1, TULP1, USHA, WDR19,600 5,600, MBG Lab P.O. Box 597, Dubai, UAE T: F: E: info@mbg.ae Web: :36PM

4 Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: 4 of 5 INHERITED CANCER PANELS Inherited Breast Cancer Panel HGC-15 HGC-153 Comprehensive Inherited Cancer Panel SOLID TUMOUR PANELS Somatic Cancer Panel (15 genes) HGC-154 HGC-155 HGC-156 Somatic Cancer Panel (6 genes) Somatic Cancer Panel (170 genes including amplification & fusion genes) SINGLE NUCLEOTIDE POLYMORPHISM ARRAYS 6 genes 56 genes 15 genes 6 genes 170 genes HGA-158 Human Whole Genome SNP Array N/A BRCA1, BRCA, CDH1, PALB, PTEN, TP53 ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKNA, CHEK, FH, FLCN, GPC3, MAX, MEN1, MET, MLH1, MRE11A, MSH, MSH6, MUTYH, NBN, NF, PALB, PHOXB, PMS, POLD1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RET, SDHAF, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, STK11, SUFU, TMEM17, TP53, TSC1, TSC, VHL, WT1, XRCC AKT1, BRAF, EGFR, ERBB, FOXL, GNA11, GNAQ, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, RET, TP53 AKT1, ALK, APC, BRAF, CDH1, CTNNB1, EGFR, ERBB, FBXW7, FGFR, FOXL, GNAQ, GNAS, KIT, KRAS, MAPk1, MET, MSH6, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SRC, STK11, TP53 ABL1, AKT1, AKT, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, AXL, BAP1, BARD1, BCL, BCL6, BRAF, BRCA1, BRCA, BRIP1, BTK, CARD11, CCND1, CCND3, CCNE1, CDK4, CDK6, CHEK1, CHEK, CSF1R, EGFR, EML4, ERBB, ERBB3, ERBB4, ERCC1, ERCC, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, EZH, FAM175A, FANCI, FANCL, FBXW7, FGF1, FGF10, FGF14, FGF19, FGF, FGF3, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR, FGFR3, FGFR4, FLI1, FLT1, FLT3, FOXL, GEN1, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH, INPP4B, JAK, JAK3, KDR, KIF5B, KIT, KMTA, KRAS, LAMP1, MAPK1, MAPK, MCL1, MDM, MDM4, MET, MLH1, MLLT3, MPL, MRE11A, MSH, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL1, MYCN, MYD88, NBN, NF1, NOTCH1, NOTCH, NOTCH3, NPM1, NRAS, NRG1, NTRK1, NTRK, NTRK3, PALB, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PMS, PPARG, PPPRA, PTCH1, PTEN, PTPN11, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RAF1, RB1, RET, RICTOR, ROS1, RPS6KB1, SLX4, SMAD4, SMARCB1, SMO, SRC, STK11, TERT, TET, TFRC, TMPRSS, TP53, TSC1, TSC, VHL, XRCC Various human SNP arrays includingloss-of-function variants, Pharmacogenomic markers, Inflammation and HLA markers, Copy number variants and other markers associated with human disease. Please contact MBG Lab for full details EDTA Blood 3,000,600 3,000 6,000 Contact MBG Will be available shortly. Contact MBG MBG Lab P.O. Box 597, Dubai, UAE T: F: E: info@mbg.ae Web: :36PM

5 Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: 5 of 5 Sample Details: EDTA blood: Fresh Tissue: : : >.5ml of blood in EDTA tube >50mg tissue in saline dampened gauze to be received within hours of operation; or snap frozen in liquid nitrogen within hours of operation and stored below -70 o C. Transport on dry ice. 5x10um sections selected by a pathologist to contain >50% viable tumour (avoid necrotic areas). Do not eat / drink for >1hour before collection. Rub swab inside the mouth with firm pressure for 1min. Place in the collection tube, seal and store between -0 o C to 5 o C. Transport within 48 hours. Notes: The Turn-around times () indicated are only inclusive of working. Samples delivered before 11:00am will begin processing immediately resulting in shorter turnaround times. The prices listed are per, please contact MBG for a discount if more than one is being requested. For other s not listed on the service list above please contact the MBG Lab for further information. Please refer to MBG-C14 Sample Collection, storage and transport guidelines. MBG Lab P.O. Box 597, Dubai, UAE T: F: E: info@mbg.ae Web: :36PM

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology

More information

Targeted Genes and Methodology Details for Epilepsy/Seizure Genetic Panels

Targeted Genes and Methodology Details for Epilepsy/Seizure Genetic Panels Targeted s and Methodology Details for Epilepsy/Seizure tic Panels Reference transcripts based on build GRCh37 (hg19) interrogated by Epilepsy/Seizure tic Panels Epilepsy Expanded Panel Epilepsy Expanded

More information

Illumina s Cancer Research Portfolio and Dedicated Workflows

Illumina s Cancer Research Portfolio and Dedicated Workflows Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,

More information

devseek (Sequence(Analysis(Panel(for(Neurodevelopmental(Disorders

devseek (Sequence(Analysis(Panel(for(Neurodevelopmental(Disorders ACSL4 Mental/retardation,/XBlinked/63 XLBR ADSL Adenylosuccinase/Deficiency AR AFF2 Mental/retardation,/XBlinked,/FRAXE/type XLBR ALG6 Congenital/disorder/of/glycosylation/type/Ic AR ANK3 Mental/retardation,/autosomal/recessive/37

More information

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018 Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations

More information

COMPLETE A FORM FOR EACH SAMPLE SUBMITTED ETHNIC BACKGROUND REPORTING INFORMATION

COMPLETE A FORM FOR EACH SAMPLE SUBMITTED ETHNIC BACKGROUND REPORTING INFORMATION DATE SAMPLE DRAWN: SAMPLE TYPE: BLOOD OTHER (SPECIFY): COMPLETE A FORM FOR EACH SAMPLE SUBMITTED PATIENT FIRST NAME: LAST NAME: DOB: SEX: M F UNKNOWN ADDRESS: HOME PHONE: ( ) WORK: ( ) EUROPEAN CAUCASIAN

More information

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15

More information

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics

More information

Requisition for DNA Testing. Reason for Referral: Patient Information: INCOMPLETE REQUESTS WILL BE BANKED. Test Requests: Sample Collection:

Requisition for DNA Testing. Reason for Referral: Patient Information: INCOMPLETE REQUESTS WILL BE BANKED. Test Requests: Sample Collection: Reason for Referral: Diagnostic Testing: Affected Unaffected Carrier testing/known Family Mutation Name of index case in the family (include copy of report): Date of Birth: Relationship to this patient:

More information

Request for expedited Result

Request for expedited Result London Health Sciences Centre Molecular Genetics Laboratories Requisition for DNA Testing DACC002 REV 20170815 AUTHORIZED SIGNATURE IS REQUIRED INCOMPLETE REQUESTS WILL BE BANKED Molecular Genetics Laboratory

More information

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial

More information

Precision Oncology: Experience at UW

Precision Oncology: Experience at UW Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,

More information

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families

More information

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

SureSelect Cancer All-In-One Custom and Catalog NGS Assays SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis

More information

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center Assessing the Economics of Genomic Medicine Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center DISCLOSURES No conflicts Patents unenforced Consultancies unpaid

More information

Plasma-Seq conducted with blood from male individuals without cancer.

Plasma-Seq conducted with blood from male individuals without cancer. Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer

More information

Subject ID: Date Test Started: Specimen Type: Peripheral Blood Date of Report: Date Specimen Obtained:

Subject ID: Date Test Started: Specimen Type: Peripheral Blood Date of Report: Date Specimen Obtained: TEST PERFORMED Whole exome sequencing (WES) with Focused Diagnostic Panel(s): Neuropathy, Leukodystrophy, Myopathy See below for a complete list of genes analyzed. RESULTS 1 sequence variant with potential

More information

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing

More information

Comprehensive genetic testing for hearing and vision loss

Comprehensive genetic testing for hearing and vision loss Comprehensive genetic testing for hearing and vision loss Hearing and vision loss can result from both genetic and non-genetic etiologies In general, there is a genetic basis for up to 50% of prelingual

More information

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST

More information

Enabling Informed Clinical Decisions with Deep Insights. Routine Multi-gene Testing for Inherited Neuromuscular Disorders

Enabling Informed Clinical Decisions with Deep Insights. Routine Multi-gene Testing for Inherited Neuromuscular Disorders Enabling Informed Clinical Decisions with Deep Insights Routine Multi-gene Testing for Inherited Neuromuscular Disorders Introduction Multi-gene Testing for Inherited Neuromuscular Disorders Inherited

More information

# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide

# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide # 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide PositiveSelect is India s widely used Cancer Genomics test with every 8 out of 10 patients opting

More information

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center

More information

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

More information

MOLECULAR SERVICES. mlabs.umich.edu

MOLECULAR SERVICES. mlabs.umich.edu MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service

More information

Epilepsy. Genetic Test Submission Guide. 2. Samples. 1. Forms. 3. Ship RESULTS. impactgenetics.com

Epilepsy. Genetic Test Submission Guide. 2. Samples. 1. Forms. 3. Ship RESULTS. impactgenetics.com Epilepsy Genetic Test Submission Guide 1. Forms 2. Samples Form 1d: If applicable Form 1b: Requisition Form Form 1a: Informed Consent 3. Ship RESULTS Impact Genetics, Dynacare 4-1100 Bennett Rd. Bowmanville,

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

DNA Genetic Cancer Risk Test. Test Report

DNA Genetic Cancer Risk Test. Test Report Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Frampton et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Supplementary Figure 1A Base substitution detection

More information

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime

More information

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor

More information

Exons from 137 genes were targeted for hybrid selection and massively parallel sequencing.

Exons from 137 genes were targeted for hybrid selection and massively parallel sequencing. SUPPLEMENTARY TABLES Supplementary Table 1. Targeted Genes ABL1 ABL2 AKT1 AKT2 AKT3 ALK APC ATM AURKA BCL2 BRAF BRCA1 BRCA2 CCND1 CCNE1 CDC73 CDH1 CDK4 CDK6 CDK8 CDKN1A CDKN2A CEBPA CHEK1 CHEK2 CREBBP

More information

Enabling Personalized

Enabling Personalized Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development

More information

Genomic Medicine: What every pathologist needs to know

Genomic Medicine: What every pathologist needs to know Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ellingford JM, Sergouniotis PI, Lennon R, et

More information

Diagnostica Molecolare!

Diagnostica Molecolare! Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE

More information

Lions and Tigers and Bears.Oh My!

Lions and Tigers and Bears.Oh My! Lions and Tigers and Bears.Oh My! TAKING THE FEAR OUT OF GENETIC TESTING Lisa Butterfield, MS, CGC Genetic Counselor Clinical Assistant Professor University of Kansas Health System Why is Genetic Testing

More information

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition.

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition. Page 1 of 10 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostics Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient

More information

Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%

Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60% Supplemental Table 1: Estimated tumor purity, allele frequency, and independent read depth for all gene mutations classified as either potentially pathogenic or VUS in the metatastic and primary tumor

More information

Clinical Grade Genomic Profiling: The Time Has Come

Clinical Grade Genomic Profiling: The Time Has Come Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation

More information

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy

More information

UKGTN Testing Criteria

UKGTN Testing Criteria UKGTN Testing Criteria Approved name and symbol of disease/condition(s): Retinal Degeneration panel test Approved name and symbol of gene(s): a panel of 105 genes, variants of which have been shown to

More information

Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax:

Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax: Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY 01234 Tel: 555-920-3333 Fax: 555-920-3334 www.moldxlaboratory.com Patient Name: Jane Doe Specimen type: Blood, peripheral DOB: 04/05/1990

More information

Accel-Amplicon Panels

Accel-Amplicon Panels Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data.

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data. Supplementary Figure 1 Depths and coverages in whole-exome and targeted deep sequencing data. Depth (top) and coverage (bottom) of whole-exome sequencing for 38 independent JPN cases (mean depth = 130)

More information

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures

More information

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition.

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition. Page 1 of 8 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostics Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 PATIENT

More information

Supplemental Information. Whole-Genome Sequencing. of a Healthy Aging Cohort

Supplemental Information. Whole-Genome Sequencing. of a Healthy Aging Cohort Cell, Volume 165 Supplemental Information Whole-Genome Sequencing of a Healthy Aging Cohort Galina A. Erikson, Dale L. Bodian, Manuel Rueda, Bhuvan Molparia, Erick R. Scott, Ashley A. Scott-Van Zeeland,

More information

COMPREHENSIVE DIAGNOSIS FOR MITOCHONDRIAL DISORDERS

COMPREHENSIVE DIAGNOSIS FOR MITOCHONDRIAL DISORDERS COMPREHENSIVE DIAGNOSIS FOR MITOCHONDRIAL DISORDERS MITOCHONDRIAL DISORDERS NGS PANELS MITOCHONDRIAL DISORDERS NGS PANELS Name Test code Gene Name Mitome200-Nuclear 2086 (164 nuclear genes) AARS2, ACACA,

More information

REQUEST FOR MOLECULAR GENETIC TESTING

REQUEST FOR MOLECULAR GENETIC TESTING PATIENT DATA CLINIC/DEPARTMENT/PRACTICE Human Genetics Diagstics Laboratory for Cytogenetics and Molecular Genetics Medical director: Prof. Dr. med. Dr. Judith Fischer Please send samples to: Institut

More information

Variant prioritization

Variant prioritization Variant prioritization University of Cambridge Marta Bleda Latorre Cambridge, UK mb2033@cam.ac.uk 30th September 2014 Research Assistant at the Department of Medicine University of Cambridge Cambridge,

More information

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 8 1.5. Primary Tumour Description... 10 1.6.

More information

Phenotype Report. Num. Positions Not Called (Missing data) Num. Variants Assessed

Phenotype Report. Num. Positions Not Called (Missing data) Num. Variants Assessed Report Date: August 19, 2015 Software Annotation Version: 8 Report Name: NA12144 NW European Genome : NA12144_S1 Sequencing Provider: Illumina Sequencing Type: Exome : Retinitis Pigmentosa Description:

More information

Table S1. Demographics of patients and tumor characteristics.

Table S1. Demographics of patients and tumor characteristics. Supplemental Tables for: A Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers Kim Hirshfield et al. Table S1. Demographics of patients and tumor characteristics.

More information

Variant association and prioritization

Variant association and prioritization Variant association and prioritization Edinburgh Genomics Marta Bleda Latorre Edinburgh, UK mb2033@cam.ac.uk 23rd October 2015 Research Assistant at the Department of Medicine University of Cambridge Cambridge,

More information

Provide your cancer patients personalized treatment options with ClariFind

Provide your cancer patients personalized treatment options with ClariFind ONCOLOGY ClariFind employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient s tumor sample to identify potential clinically actionable targets and associated therapies.

More information

Clinical Diagnosis of Mendelian Disorders Using a Comprehensive Gene-Targeted Panel Test for Next-Generation Sequencing

Clinical Diagnosis of Mendelian Disorders Using a Comprehensive Gene-Targeted Panel Test for Next-Generation Sequencing Yonago Acta medica 2016;59:118 125 Original Article Clinical Diagnosis of Mendelian Disorders Using a Comprehensive Gene-Targeted Panel Test for Next-Generation Sequencing Tetsuya Okazaki,* Megumi Murata,

More information

Versus. Cancer genomics Competitive Analysis

Versus. Cancer genomics Competitive Analysis Cancer genomics Competitive Analysis Versus AGH Competitor #1 MYRIAD GENETICS, INC. Headquarters: UT, USA & Switzerland Publicly Traded Company - MYGN Founded: 1992 Company Size: 1001-5000 employees (source:

More information

Out-Patient Billing CPT Codes

Out-Patient Billing CPT Codes Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB

More information

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection

More information

PRICE AND TEST LIST January 4, 2018 (by Test Code)

PRICE AND TEST LIST January 4, 2018 (by Test Code) Test Code Test Description TAT Price 2018 CPT Codes WHOLE EXOME SEQUENCING WES001 MNG Exome TM Trio Sequencing and Copy Number Analysis + mtdna (Proband + 2 Family Members) 2-4 Weeks $6,900.00 81415, 81416,

More information

The University of Chicago Genetic Services Laboratories

The University of Chicago Genetic Services Laboratories Aceruloplasminemia testing CP sequencing Aceruloplasminemia CP deletion/duplication Albinism testing Albinism Sequencing Panel (20 genes Albinism Deletion/Duplication Panel (20 genes Alstrom syndrome testing

More information

TGL clinical User Guide

TGL clinical User Guide TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7 TGL clinical This document describes the services provided by TGL clinical

More information

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6 Page 1 of 6 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostic Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient

More information

Illumina Clinical Services Laboratory

Illumina Clinical Services Laboratory Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Predisposition Screen Requisition Form The TruGenome Predisposition Screen is intended

More information

Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014

Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014 Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014 Please note that this listing includes the most recent codes provided by the American Medical Association (AMA), and that it is subject to

More information

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B1-0916 and B1-0713. Copy number changes of the human chromosome 8 are common in many types of tumours. In most cases, losses of 8p sequences and gains of 8q

More information

Whole Exome Sequencing (WES): Questions and Answers for Providers

Whole Exome Sequencing (WES): Questions and Answers for Providers Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing?... 2 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus

More information

A brain tumor and NGS/multiplexing

A brain tumor and NGS/multiplexing A brain tumor and NGS/multiplexing Santiago Ramón y Cajal Jefe de Servicio. Hospital Vall d Hebron Catedrático de Anatomía Patológica U.A.B. Académico de Número de la Real Academia Nacional de Medicina

More information

Leistungsverzeichnis

Leistungsverzeichnis Leistungsverzeichnis SYNLAB MVZ Humangenetik Mannheim Genetische Beratung / Molekulargenetische Diagnostik / Molekulare Zytogenetik / Abstammungsgutachten und Vaterschaftstest www.zhma.de Akkreditiert

More information

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

Informed Consent Columbia Whole Genome or Whole Exome Sequencing Informed Consent Columbia Whole Genome or Whole Exome Sequencing Please read the following form carefully and discuss with your ordering physician before signing consent. This consent is intended for the

More information

Patient information / fill out completely

Patient information / fill out completely Surname and initials Name spouse Street name and number Postal code and city Country Date of birth Sex Patient information / fill out completely PROCEDURE: Always consult us prior to sending material other

More information

PRICE AND TEST LIST August 24, 2018 (by Test Code)

PRICE AND TEST LIST August 24, 2018 (by Test Code) Test Code Test Description TAT Price 2018 CPT Codes WHOLE GENOME SEQUENCING WGS001 MNGenome TRIO Sequencing 2-6 Weeks Call 81425, 81426 x2 WGS003 MNGenome Proband Only Sequencing 2-6 Weeks Call 81425 WHOLE

More information

Test Information Sheet

Test Information Sheet Combined Cardiac Panel Test Information Sheet Panel Gene List: ABCC9, ACTC1, ACTN2, AKAP9, ALMS1, ALPK3, ANK2, ANKRD1, BAG3, BRAF, CACNA1C, CACNA2D1, CACNB2, CALM1, CALM2, CALM3, CASQ2, CAV3, CHRM2, CRYAB,

More information

NeoTYPE Cancer Profiles

NeoTYPE Cancer Profiles NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What

More information

NeoTYPE Cancer Profiles

NeoTYPE Cancer Profiles NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE

More information

Paediatric Cardiomyopathy

Paediatric Cardiomyopathy Paediatric Cardiomyopathy Contact details: Bristol Genetics Laboratory Pathology Sciences Southmead Hospital Bristol, BS10 5NB Enquiries: 0117 414 6174 FAX: 0117 414 6464 Head of department: Eileen Roberts

More information

Achromatopsia NGS 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H ARMS2, CFH Sequencing PAX6 MLPA 1 PAX6

Achromatopsia NGS 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H ARMS2, CFH Sequencing PAX6 MLPA 1 PAX6 Asper Ophthalmics Achromatopsia 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H 05 Age-related Macular Degeneration 5 ABCA4, ARMS2, C2, C3, C9, CFB, CFH, CFI, 995* CST3, CX3CR, ERCC6, FBLN5, HMCN, HTRA, RAX2

More information

A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol

A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol Topics to be covered How pathology contributes to genetic diagnosis

More information

NGS in Diagnostics: a practical example in hereditary cardiomyopathies

NGS in Diagnostics: a practical example in hereditary cardiomyopathies NGS in Diagnostics: a practical example in hereditary cardiomyopathies Patricia Norambuena University Hospital Motol, Prague. 2 nd Faculty of Medicine, Charles University VEP Course - November 6 th - 8th,

More information

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

Next generation histopathological diagnosis for precision medicine in solid cancers

Next generation histopathological diagnosis for precision medicine in solid cancers Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics

More information

Ethical Challenges of Genome-based Cancer Research: Return of individual research results

Ethical Challenges of Genome-based Cancer Research: Return of individual research results Ethical Challenges of Genome-based Cancer Research: Return of individual research results Gail P. Jarvik, M.D., Ph.D. Arno G. Motulsky Endowed Chair Medicine and Genome Sciences Head, Medical Genetics

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility

More information

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City

More information

Family Education and Support

Family Education and Support Family Education and Support Key Topics First Aid Seizure Safety Sports Physical Activity Driving Familial Psychosocial Needs in Treating Pediatric Epilepsy Poll Question 1 Which of the following is not

More information

NEXT GENERATION SANGER SEQUENCING PLATFORMS (NGS)

NEXT GENERATION SANGER SEQUENCING PLATFORMS (NGS) NEXT GENERATION SANGER SEQUENCING PLATFORMS (NGS) Category Disease Category Disease Number of Genes Genes Comment Test Specification Price in Next Generation and Sanger Sequencing Platforms (NGS) Cancer

More information

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a

More information

Genetic testing for hereditary cancer

Genetic testing for hereditary cancer Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

Achromatopsia NGS 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H ARMS2, CFH Sequencing PAX6

Achromatopsia NGS 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H ARMS2, CFH Sequencing PAX6 Disease/Condition name Method No of Asper Ophthalmics Achromatopsia 6 ATF6, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H 05 Age-related Macular Degeneration 2 ABCA4, ARMS2, C2, C3, C9, CCR3, CFB, CFH, 995* CFI, CST3,

More information

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome

More information

Hematology Fusion/Expression Profile

Hematology Fusion/Expression Profile Hematology Fusion/Expression Profile Patient Name: Ordered By Date of Birth: Ordering Physician: Gender (M/F): Physician ID: Client: Accession #: Case #: Specimen Type: Body Site: Specimen ID: Ethnicity:

More information

Comprehensive Test Menu August 2018

Comprehensive Test Menu August 2018 Comprehensive Test Menu August 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21

More information

Secuenciación masiva: papel en la toma de decisiones

Secuenciación masiva: papel en la toma de decisiones Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.

More information

Webinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts

Webinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels April 13, 2016 Webinar Series Brought to you by the Science/ AAAS Custom Publishing Office Participating

More information

MEDICAL POLICY Genetic Testing

MEDICAL POLICY Genetic Testing POLICY.........PG0041 EFFECTIVE......01/01/12 LAST REVIEW... 03/24/17 MEDICAL POLICY Genetic Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by

More information

Click to edit Master /tle style

Click to edit Master /tle style Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics

More information